KRAS and neoplasm: The rates of mutations in key oncogenes, such as KRAS, TP53, or PIK3CA, were not statistically different between the groups, indicating that the observed differences in response rates were likely driven by treatment effects rather than intrinsic tumor genetics (eTable 4 in Supplement 2).